These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 34408401)

  • 1. Efficacy, Pharmacokinetics, Biodistribution and Excretion of a Novel Acylated Long-Acting Insulin Analogue INS061 in Rats.
    Pan K; Shi X; Liu K; Wang J; Chen Y
    Drug Des Devel Ther; 2021; 15():3487-3498. PubMed ID: 34408401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
    Goldman J; Kapitza C; Pettus J; Heise T
    Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
    Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
    Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
    Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
    Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, tissue distribution and excretion of a novel long-acting human insulin analogue - recombinant insulin LysArg in rats.
    Cui T; Li Y; Wei Z; Zhang X; Li W; Zhou W; Lu J; Li J; Yi X; Zeng Y; Liu C; Yan F
    Xenobiotica; 2021 Mar; 51(3):307-315. PubMed ID: 33151101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
    Vora J; Heise T
    Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region.
    Nosek L; Coester HV; Roepstorff C; Thomsen HF; Kristensen NR; Haahr H; Heise T
    Clin Drug Investig; 2014 Sep; 34(9):673-9. PubMed ID: 25124362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peak-less hypoglycemic effect of insulin glargine by complexation with maltosyl-β-cyclodextrin.
    Uehata K; Anno T; Hayashida K; Higashi T; Motoyama K; Hirayama F; Uekama K; Arima H
    Int J Pharm; 2012 Jan; 422(1-2):33-9. PubMed ID: 22020273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: Investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats.
    Cilek A; Celebi N; Tirnaksiz F; Tay A
    Int J Pharm; 2005 Jul; 298(1):176-85. PubMed ID: 15950411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats.
    Li XG; Li L; Zhou X; Chen Y; Ren YP; Zhou TY; Lu W
    Acta Pharmacol Sin; 2012 Nov; 33(11):1379-86. PubMed ID: 22659626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
    Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
    Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of liver function, antioxidant responses, insulin resistance and glucose transport by Oroxylum indicum stem bark in STZ induced diabetic rats.
    Singh J; Kakkar P
    Food Chem Toxicol; 2013 Dec; 62():722-31. PubMed ID: 24140466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
    Martin GJ; Rand JS
    J Feline Med Surg; 2001 Mar; 3(1):23-30. PubMed ID: 11716627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
    Biester T; Danne T; Bläsig S; Remus K; Aschemeier B; Kordonouri O; Bardtrum L; Haahr H
    Pediatr Diabetes; 2016 Dec; 17(8):642-649. PubMed ID: 26782928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart.
    Jacobsen LV; Søgaard B; Riis A
    Eur J Clin Pharmacol; 2000 Aug; 56(5):399-403. PubMed ID: 11009049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
    Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short- and Longterm Glycemic Control of Streptozotocin-Induced Diabetic Rats Using Different Insulin Preparations.
    Luippold G; Bedenik J; Voigt A; Grempler R
    PLoS One; 2016; 11(6):e0156346. PubMed ID: 27253523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glargine and degludec: Solution behaviour of higher dose synthetic insulins.
    Adams GG; Alzahrani Q; Jiwani SI; Meal A; Morgan PS; Coffey F; Kok S; Rowe AJ; Harding SE; Chayen N; Gillis RB
    Sci Rep; 2017 Aug; 7(1):7287. PubMed ID: 28779138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
    Zhang SQ; Zhong XY; Chen GH; Lu WL; Zhang Q
    J Pharm Pharmacol; 2008 Jan; 60(1):99-105. PubMed ID: 18088510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.